AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 ...
The Pharma Letter

AbbVie punts up to ~$5 billion on RemeGen bispecific antibody

US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, ...
Contract Pharma

AbbVie, RemeGen Partner on Novel Bispecific Antibody for Advanced Tumors

AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...
Medical Dialogues

Correlation between cancer cachexia and immune-related adverse events in HCC: Study

Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) ...
News Medical

Researchers identify new molecular switch involved in programmed cell death

In the fight against disease, programmed cell death – also known as apoptosis – is a key protective function of the body. It breaks down cells that are damaged or have undergone dangerous changes.
Frontiers

Biomarker-Guided Strategies in NSCLC Immunotherapy

The field of immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), particularly ...
Pharmabiz

AbbVie & RemeGen enter exclusive licensing agreement to develop novel bispecific antibody for advanced solid tumours

AbbVie & RemeGen enter exclusive licensing agreement to develop novel bispecific antibody for advanced solid tumours: North Chicago, Illinois Tuesday, January 13, 2026, 14:00 Hrs ...